HDLBP/Vigilin siRNA Compositions for Lipid Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders of lipid metabolism, such as high cholesterol levels, often rely on statins which can have side effects and rare but severe adverse effects, necessitating the need for alternative therapeutic approaches.
Innovation Solution
Development of iRNA compositions that mediate the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of the High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, using double-stranded ribonucleic acid (dsRNA) agents to inhibit Hdlbp/Vigilin expression, thereby reducing lipid levels and atherosclerotic plaque formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statins are used to treat high cholesterol levels, then cholesterol levels are reduced, but side effects and severe adverse effects occur
Solution Approach 1:
The patent uses iRNA molecules as intermediaries to achieve cholesterol reduction. Instead of using statins that directly inhibit HMG-CoA reductase and cause side effects, the iRNA molecules specifically target and degrade HMGCR mRNA, preventing the production of the target enzyme. This intermediary approach allows for more selective gene silencing with potentially fewer off-target effects.
Solution Approach 2:
The patent replaces the mechanical/enzymatic inhibition mechanism of statins with an RNA-based molecular biology mechanism. Statins work by competitively inhibiting the enzyme HMG-CoA reductase, while the iRNA composition uses RNA interference to specifically degrade the mRNA transcript of HMGCR, thereby preventing enzyme synthesis at the transcriptional level. This substitution enables more precise targeting.
2Object-affected harmful factors
If alternative treatments to statins are developed, then side effects are reduced, but treatment efficacy must be maintained
Solution Approach 1:
The patent employs various chemical modifications to the iRNA molecules (such as 2'-O-methyl modifications, phosphorothioate backbone modifications) to optimize their stability, cellular uptake, and gene silencing efficacy. These parameter changes in the molecular structure of the therapeutic agent enhance its effectiveness while maintaining safety, providing a balance between efficacy and reduced side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents specifically target and reduce Hdlbp/Vigilin gene expression, leading to decreased plasma cholesterol, triglyceride, and VLDL levels, improved insulin sensitivity, and reduced atherosclerotic plaque formation, providing a potential alternative to statins with fewer side effects.
Implementation Method 1
iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene
Data Source
AI summary
The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.